Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 676.70K | 799.10K | 1.05M | 640.00K | |
| Depreciation & Amortization | 130.20K | 126.60K | 132.10K | 84.80K | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 808.20K | 927.40K | 1.19M | 726.40K | |
| Operating Income | -808.20K | -927.40K | -1.19M | -726.40K | |
| Income Before Tax | -798.70K | -911.20K | -3.18M | -726.90K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -798.70K | -911.20K | -3.18M | -726.90K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -798.70K | -911.20K | -3.18M | -726.90K | |
| EBIT | -808.20K | -927.40K | -1.19M | -726.40K | |
| EBITDA | -725.50K | -866.80K | -1.14M | -641.60K | |
| EPS Basic | -0.01 | -0.02 | -0.06 | -0.02 | |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | |
| EPS Diluted | -0.01 | -0.02 | -0.07 | -0.02 | |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | |
| Average Basic Shares Outstanding | 53.83M | 53.76M | 49.78M | 42.66M | |
| Average Diluted Shares Outstanding | 53.83M | 53.76M | 49.78M | 42.66M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |